Disclaimer

The following statements do not represent an offer for sale or an invitation to raise a bid or an offer for subscription of shares of Oroscience Plc. At present, no prospectus has been lodged* at the Bundesanstalt für Finanzdienstleistungsaufsicht (i.e. a Federal Security Office for Financial Services, hereafter BaFin). Therefore Oroscience Plc provides the following information exclusively to qualified parties. All other people are asked to await the lodgement and promulgation of the respective prospectus.

Financial institution, insurance company, investment company
or any other legal person under § 3 sec. 6 lit. a) WpPG [3]

Juristic person exceeding 250 employees, total assets exceeding 43 billion € and
an annual net turnover of more than 50 Mio. €

Other juristic persons registered under § 27 WpPG

Private people registered under § 27 WpPG

Others

Please peruse the following advice:

1. We Are Not Offering Securities or Providing Investment Advice

The following statements do not represent an offer for sale or an invitation to raise a bid or an offer for subscription of shares of Oroscience Plc. At present, no prospectus has been lodged at the BaFin.

2. Do Not Rely on Forward-Looking Information

Some of the statements on our web site, including those relating to Oroscience’s business and project plans, are considered forward-looking statements within the meaning of some securities laws. Forward-looking statements give our expectations or forecasts of future events. Sometimes these statements will use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “belief,” “outlook,” “forecast”, and other similar words. These statements are not guarantees of our future performance and are subject to risks, uncertainties and other important factors that could cause our actual performance to be materially different from those we project.

Given these uncertainties, you should not rely on forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date that they initially were made. We expressly disclaim a duty to provide updates to any forward-looking statements, and the estimates and assumptions associated with them, to reflect events or circumstances or changes in expectations or the occurrence of anticipated events after the date they initially were made, except and to the extend required by applicable law.

Yes, I agree to the preceding information which I have read and comprehended the meaning thereof.

No, I either have not read the preceding information, do not comprehend the meaning thereof, or do not agree to their validity.

 

Oroscience

Based in Palo Alto, CA, the innovation center of Silicon Valley, we're dedicated to bringing the best wound healing science to our clinician partners and the patients in their care.

What Clinicians are saying:

Connective Tissue Graft

"At the 14 day post-op appointment, the sutures were removed, and the soft tissues appeared clinically to be in an advanced state of healing."

Bryan Pearson, DDS, MS

Full Mouth Extraction and Immediate Implants

"For demanding cases where optimal soft tissue healing is of paramount importance to the overall success, I feel that using Periogenix significantly enhances the final results."

J. Jerome Smith, DDS